ORGOVYX
Total Payments
$21.7M
Transactions
72,261
Doctors
13,240
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $8.7M | 18,890 | 6,237 |
| 2023 | $5.9M | 18,323 | 6,524 |
| 2022 | $2.5M | 18,110 | 6,276 |
| 2021 | $4.6M | 16,938 | 6,366 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16.5M | 1,880 | 76.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.6M | 1,040 | 12.2% |
| Food and Beverage | $1.4M | 66,765 | 6.6% |
| Consulting Fee | $635,803 | 125 | 2.9% |
| Travel and Lodging | $277,298 | 746 | 1.3% |
| Honoraria | $136,668 | 55 | 0.6% |
| Education | $38,441 | 1,648 | 0.2% |
| Grant | $5,530 | 2 | 0.0% |
Payments by Type
Research
$16.5M
1,880 transactions
General
$5.2M
70,381 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | Sumitomo Pharma America, Inc. | $5.1M | 0 |
| RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | Sumitomo Pharma America, Inc. | $4.4M | 0 |
| A TWO-PART, OPEN-LABEL, FIXED-SEQUENCE, TWO-PERIOD CROSSOVER STUDY TO ASSESS THE EFFECTS OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF RELUGOLIX, ESTRADIOL AND NORETHINDRONE AFTER ADMINISTRATION OF THE RELUGOLIX/ESTRADIOL/NORETHINDRONE ACETATE FIXED-DOSE COMBINATION TABLET IN HEALTHY POSTMENOPAUSAL WOMEN OR OF RELUGOLIX AFTER ADMINISTRATION OF A SINGLE 120-MG DOSE IN HEALTHY ADULT MEN | Myovant Sciences GmbH | $2.2M | 0 |
| A TWO-PART, OPEN-LABEL, FIXED-SEQUENCE, TWO-PERIOD CROSSOVER STUDY TO ASSESS THE EFFECTS OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF RELUGOLIX, ESTRADIOL AND NORETHINDRONE AFTER ADMINISTRATION OF THE RELUGOLIX/ESTRADIOL/NORETHINDRONE ACETATE FIXED-DOSE COMBINATION TABLET IN HEALTHY POSTMENOPAUSAL WOMEN OR OF RELUGOLIX AFTER ADMINISTRATION OF A SINGLE 120-MG DOSE IN HEALTHY ADULT MEN | Sumitomo Pharma America, Inc. | $1.5M | 0 |
| HERO STUDY GRANT | Myovant Sciences Inc. | $843,973 | 0 |
| AN OPEN-LABEL, FIXED (SINGLE)-SEQUENCE CROSSOVER STUDY TO ASSESS THE SUFFICIENCY OF DOSE SEPARATION TO MITIGATE ABSORPTION MEDIATED INCREASES IN EXPOSURE TO RELUGOLIX RESULTING FROM INHIBITION OF INTESTINAL P-GP BY AZITHROMYCIN IN HEALTHY ADULT MEN | Myovant Sciences GmbH | $797,660 | 0 |
| MECHANISM AND PREDICTORS OF CARDIOTOXICITY AFTER PROSTATE CANCER TREATMENT A PARALLEL COHORT AND RANDOMIZED TRIAL COMPARING RADIATION ALONE RADIATION PLUS LEUPROLIDE AND RADIATION PLUS RELUGOLIX | PFIZER INC. | $742,476 | 0 |
| AN OPEN-LABEL, FIXED SINGLE -SEQUENCE CROSSOVER STUDY TO ASSESS THE SUFFICIENCY OF DOSE SEPARATION TO MITIGATE ABSORPTION MEDIATED INCREASES IN EXPOSURE TO RELUGOLIX RESULTING FROM INHIBITION OF INTESTINAL P-GP BY AZITHROMYCIN IN HEALTHY ADULT MEN | Myovant Sciences GmbH | $446,389 | 0 |
| A COMPARISON OF RELUGOLIX VS ELIGARD AND CARDIOVASCULAR FUNCTION AND BIOMARKERS DURING COMBINED ADTRADIATION FOR PROSTATE CANCER | PFIZER INC. | $100,000 | 0 |
| PHASE IB TRIAL OF RELUGOLIX AND ENZALUTAMIDE AS NEOADJUVANTADJUVANT TO LOCALREGIONAL TREATMENT IN PATIENTS WITH HIGHRISK LOCALLY ADVANCED PROSTATE CANCER | PFIZER INC. | $100,000 | 0 |
| QUANTIFYING OPTIMAL RELUGOLIX DURATION WITH RADIATION IN HIGH RISK PROSTATE CANCER | PFIZER INC. | $100,000 | 0 |
| RANDOMIZED CONTROLLED TRIAL OF RELUGOLIX PLUS ABIRATERONE ACETATE AA VERSUS LEUPROLIDE PLUS AA FOR ADVANCED PROSTATE CANCER REVELUTION2 | PFIZER INC. | $100,000 | 0 |
| THE SUGAR STUDY SBRT AND ULTRASHORT GNRH ANTAGONISTRELUGOLIX FOR CLINICOGENOMIC UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER | PFIZER INC. | $100,000 | 0 |
| RELUGOLIX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $60,960 | 11 |
| RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPENLABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACECV) | Sumitomo Pharma America, Inc. | $22,633 | 0 |
| AN INTERNATIONAL PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY OF RELUGOLIX WITH ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS | Myovant Sciences Inc. | $15,539 | 0 |
| ORGOVYX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,900 | 6 |
| A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS | Sumitomo Pharma America, Inc. | $7,725 | 7 |
| PUBLICATION DEVELOPMENT SUPPORT IN RELATION TO THE HISTORICAL OVERVIEW OF METASTATIC PROSTATE CANCER THERAPY AND GONADTROPIN-RELEASING HORMONE ANTAGONISTS INCLUDING RELUGOLIX | Myovant Sciences Inc. | $3,075 | 1 |
Top Doctors Receiving Payments for ORGOVYX — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Urology | Melrose Park, IL | $42,320 | 33 |
| , MD PHD | Radiation Oncology | Los Angeles, CA | $41,015 | 41 |
| , MD | Medical Oncology | Chicago, IL | $40,780 | 16 |
| , MD | Student in an Organized Health Care Education/Training Program | Hendersonville, TN | $40,186 | 103 |
| , MD | Urology | Orange, CA | $39,136 | 38 |
| , M.D | Hematology & Oncology | Cary, NC | $37,751 | 39 |
| , MD | Urology | Wichita, KS | $36,644 | 23 |
| , M.D | Urology | Baltimore, MD | $31,455 | 36 |
| , M.D | Urology | Lancaster, PA | $30,276 | 50 |
| , M.D | Nephrology | Woodside, CA | $29,813 | 1 |
| , M.D | Urology | Chicago Ridge, IL | $29,180 | 63 |
| , MD | Diagnostic Radiology | Duluth, MN | $28,661 | 20 |
| , MD | Cardiovascular Disease | Los Angeles, CA | $28,543 | 11 |
| , M.D | Urology | La Mesa, CA | $28,393 | 95 |
| , MD | Internal Medicine | Dallas, TX | $26,424 | 8 |
| , M.D | Urology | Roseville, CA | $24,829 | 31 |
| , M.D | Urology | Boston, MA | $24,385 | 13 |
| , MD PHD | Urology | Dallas, TX | $23,096 | 14 |
| , MD | Urology | Durham, NC | $22,747 | 34 |
| , M.D | Urology | Denver, CO | $22,136 | 34 |
| , M.D | Radiation Oncology | Clarkston, MI | $19,864 | 32 |
| , M.D | Urology | El Paso, TX | $17,515 | 34 |
| , M.D | Urology | Durham, NC | $16,909 | 7 |
| , APRN | Family | Salt Lake City, UT | $16,338 | 12 |
| , M.D | Radiation Oncology | Atlanta, GA | $15,893 | 10 |
Ad
Manufacturing Companies
- Sumitomo Pharma America, Inc. $12.8M
- Myovant Sciences GmbH $3.4M
- Myovant Sciences Inc. $3.1M
- PFIZER INC. $2.3M
- Pfizer Inc. $44,718
- MEDIVATION SERVICES LLC $456.86
Product Information
- Type Drug
- Total Payments $21.7M
- Total Doctors 13,240
- Transactions 72,261
About ORGOVYX
ORGOVYX is a drug associated with $21.7M in payments to 13,240 healthcare providers, recorded across 72,261 transactions in the CMS Open Payments database. The primary manufacturer is Sumitomo Pharma America, Inc..
Payment data is available from 2021 to 2024. In 2024, $8.7M was paid across 18,890 transactions to 6,237 doctors.
The most common payment nature for ORGOVYX is "Unspecified" ($16.5M, 76.2% of total).
ORGOVYX is associated with 19 research studies, including "A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX" ($5.1M).